https://www.selleckchem.com/pr....oducts/Gefitinib.htm
OBJECTIVES In juvenile dermatomyositis (JDM), a heterogeneous systemic immune-mediated vasculopathy, we aim to 1) identify inflammation/endothelial dysfunction-related biomarker profiles reflecting disease severity at diagnosis; 2) establish if biomarker profiles can predict response to treatment. METHODS 39 markers related to endothelial activation, dysfunction and inflammation were measured in treatment-naive JDM patient serum from two independent cohorts (n=30/n=29) by multiplex technology. Data were analyzed by unsupervised hierar
Like
Comment
Share
